Many leading funds filed forms 13-D and 13-G (and form 4) with the SEC on Friday, indicating that they had amended their ownership in U.S. traded public companies. Also, we have included, when applicable, SEC Form 4 filings by Institutions that are considered corporate insiders by virtue of their holding more than 10% ownership, and in many cases having representation on the Board of Directors. The following are the most notable filings on Friday (for more info on Forms 13-D and 13-G, and how to interpret that, please refer to the end of this article):
Mosaic Inc. (MOS): The Mosaic Company is one of the world's leading producers and marketers of concentrated phosphate and potash crop nutrients for the global agriculture industry. On Friday, Temasek Holdings, the government of Singapore's $156 billion investment company, one of the many sovereign wealth funds, and with $1.5 billion in 13-F assets per its latest Q3 13-F filing, filed SEC Form SC 13G/A indicating that it holds 20.0 million shares, an increase from the 17.9 million shares it indicated it held in a prior SC 13G filing on December 20th, and well over the 0.1 million shares it held at the end of Q3.
MOS has been weak for the past year, down about 30%, and it trades at 11-12 forward P/E and 2.2 P/B compared to averages of 10.1 and 3.6 for its peers in the fertilizer group, while earnings are projected to increase from $4.38 in 2011 to $5.14 in 2013 at an annual growth rate of 8.3%.
Oclaro Inc. (OCLR): OCLR manufactures transmitters, modulators, receiver, transceivers, laser chips and amplifiers used in optical networks. On Friday, Bloomington, MN-based Kopp Investment Advisors, with $238 million in 13-F assets per its latest Q4 13-F filing, filed SEC Form SC 13D/A indicating that it holds 3.1 million or 6.0% of outstanding shares, an increase from the 2.5 million shares it indicated it held in a prior SC 13D filing on January 20th.
The move makes them the second largest institutional holder of OCLR, behind first place Fidelity Investments that holds 3.3 million shares. Also, although the filing is a SC 13D which usually indicates that the filer has taken an activist stance, Kopp explicitly indicates in the filing that the shares acquired were not for the purpose of changing or influencing the control of the company; rather they were acquired for only (passive) investment purposes.
Oncothyreon Inc. (ONTY): ONTY develops synthetic vaccines and targeted small molecules for cancer immunotherapy and management. Its primary product candidate, Stimuvax is in phase 3 clinical trials for the treatment of non-small cell lung cancer (NSCLC). On Friday, private investor Steven Newby filed SEC From SC 13G indicating that he holds 2.55 million or 6.0% of ONTY. We could not find any other filings for Mr. Newby, so this appears to be a new position; however, with 2.55 million shares, it also makes his position smaller than only the largest institutional shareholder Viking Global Investors that holds 3.1 million shares. ONTY shares are up strongly by about 150% in the past year, based mostly on positive clinical data from its Stimuvax® cancer vaccine in non-small cell lung cancer, and its PI-3 Kinase Inhibitor PX-866 in Glioblastoma, and bolstered by outperform ratings from brokers Wedbush and Rodman & Renshaw.
New Oriental Education & Technology ADS (EDU): EDU is a Chinese provider of foreign language training and test preparation courses for admissions and assessment tests in the U.S., the PRC and Commonwealth countries. In addition, it also offers primary and secondary school education, development and distribution of educational content, software and other technology, and online education. On Friday, JPMorgan Chase & Co. (JPM) filed SEC Form SC 13G/A indicating that it holds 8.7 million or 5.5% of outstanding shares, a decrease from the 9.2 million shares it held at the end of Q3. EDU trades at a premium 27 P/E on a TTM basis versus a 13.1 average for its peers in the schools group.
Credit: Fundamental data in this article were based on SEC filings, I-Metrix® by Edgar Online®, Zacks Investment Research, Thomson Reuters and Briefing.com. The information and data is believed to be accurate, but no guarantees or representations are made.
Disclaimer: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our 'opinions' and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.